Core Insights - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, with key developments in obesity and liver disease treatments [3]. Company Overview - The company is developing DA-1726, a novel oxyntomodulin (OXM) analogue, aimed at treating obesity. It acts as a dual agonist for glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), potentially leading to superior weight loss compared to selective GLP1R agonists [3]. - DA-1726 has shown best-in-class potential in a Phase 1 multiple ascending dose trial, demonstrating effectiveness in weight loss, glucose control, and waist reduction [3]. - MetaVia is also developing DA-1241, a G-protein-coupled receptor 119 (GPR119) agonist, for treating Metabolic Dysfunction-Associated Steatohepatitis (MASH). Pre-clinical studies indicate its positive effects on liver inflammation, lipid metabolism, weight loss, and glucose metabolism [3]. - In a Phase 2a clinical study, DA-1241 exhibited direct hepatic action alongside glucose-lowering effects, reducing hepatic steatosis, inflammation, and fibrosis [3]. Conference Participation - President and CEO Hyung Heon Kim will present at the H.C. Wainwright Liver Disease Virtual Conference on October 21-22, 2025, with CFO Marshall H. Woodworth participating in one-on-one meetings [1][2].

Core Insights - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, currently developing two key drug candidates: DA-1726 for obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [4] Company Overview - MetaVia is developing DA-1726, a novel oxyntomodulin (OXM) analogue that acts as a dual agonist for glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), showing potential for superior weight loss and glucose control compared to selective GLP1R agonists [4] - DA-1726 demonstrated best-in-class potential in a Phase 1 multiple ascending dose trial, indicating effectiveness in weight loss, glucose control, and waist reduction [4] - DA-1241 is a G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of gut peptides GLP-1, GIP, and PYY, showing positive effects on liver inflammation, lipid metabolism, and glucose metabolism in pre-clinical studies [4] - In a Phase 2a clinical study, DA-1241 exhibited direct hepatic action alongside glucose-lowering effects [4] Upcoming Events - MetaVia will participate in several upcoming conferences, including: - Wells Fargo Healthcare Conference from September 3-5, where CEO Hyung Heon Kim will attend [7] - H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, featuring a fireside chat and an on-demand presentation available from September 5 [7] - Obesity Science & Innovation 2025 Congress on September 16-17, where Mr. Kim will present an overview focusing on DA-1726 [7] - Fierce Biotech Week from October 7-9, with Mr. Kim's attendance [7]

Core Insights - MetaVia Inc. has initiated the first patient dosing in the 8-week 48 mg multiple ascending dose (MAD) cohort of its Phase 1 clinical trial for DA-1726, targeting obesity, with top-line data expected in Q4 2025 [1][2] - The company has signed a collaboration with Syntekabio to explore additional indications for DA-1241 beyond Metabolic Dysfunction-Associated Steatohepatitis (MASH) [1][5] - As of the end of Q2 2025, MetaVia reported $17.6 million in cash, which is anticipated to fund operations into 2026 [1][6] Clinical Development - DA-1726 is a dual agonist targeting GLP1R and GCGR, showing promising results in previous cohorts with an average weight loss of 4.3% and a maximum of 6.3% at the 32 mg dose [2][4] - The 48 mg cohort aims to evaluate longer-term efficacy and safety, building on the favorable safety profile observed in earlier trials [2][3] - DA-1241 has shown potential in reducing liver fat and inflammation when combined with an FGF21 analogue, with ongoing efforts to schedule an end-of-Phase 2 meeting with the FDA [2][5] Financial Performance - R&D expenses for Q2 2025 were approximately $2.3 million, a significant decrease from $8.1 million in Q2 2024, primarily due to lower direct expenses related to both DA-1241 and DA-1726 [4][6] - The net loss for Q2 2025 was $4.0 million, or $0.26 per share, compared to a net loss of $10.1 million, or $1.85 per share, in Q2 2024 [6][12] - Total operating expenses for Q2 2025 were approximately $4.3 million, down from $10.1 million in the same period last year, reflecting reduced R&D spending [6][12] Strategic Collaborations - The collaboration with Syntekabio aims to leverage AI for identifying new indications for DA-1241, enhancing its therapeutic profile [2][5] - MetaVia's partnership with Dong-A ST has facilitated funding and development efforts, with a recent private placement raising $10 million [5][6] Company Overview - MetaVia Inc. focuses on developing innovative therapies for cardiometabolic diseases, with DA-1726 and DA-1241 as its lead candidates [7]

Core Insights - MetaVia Inc. has extended the Phase 1 clinical trial of DA-1726 from 4 weeks to 8 weeks to assess early efficacy, patient safety, and tolerability with longer-term exposure [1][2] - Top-line data from the extended trial is expected in the fourth quarter of 2025 [1] Company Overview - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, currently developing DA-1726 for obesity treatment and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [6] - DA-1726 is a novel oxyntomodulin (OXM) analogue that acts as a dual agonist for GLP-1 and glucagon receptors, potentially leading to superior weight loss compared to selective GLP-1 agonists [4][6] Clinical Trial Details - The Phase 1 trial is a randomized, double-blind, placebo-controlled study involving healthy adults with a BMI between 30 – 45 kg/m2 [2] - The trial's primary endpoint is to assess the safety and tolerability of DA-1726, while secondary endpoints include pharmacokinetics and exploratory endpoints focus on metabolic and cardiac parameters [2][5] Drug Efficacy and Safety - Previous data from the 32 mg dose of DA-1726 indicated a mean weight loss of 4.3% and a maximum of 6.3% by Day 26, with 83% of patients experiencing early satiety [2][5] - DA-1726 demonstrated a favorable safety profile, with a mild, transient gastrointestinal profile, and a differentiated tolerability compared to existing GLP-1 therapies [2][4] Future Outlook - The extension of the trial aims to provide more robust data that may position DA-1726 more strongly against current treatments and those in late-stage clinical trials [2] - The company anticipates that the results from the extended cohort will further validate DA-1726's longer-term safety and efficacy [2]

Core Insights - MetaVia Inc. has announced a research collaboration with Syntekabio to enhance the therapeutic potential of its oral GPR119 agonist, DA-1241, by identifying additional disease targets and optimizing its therapeutic profile [1][3] Company Overview - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, currently developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and type 2 diabetes (T2D) [6] - Syntekabio, a drug discovery company, utilizes AI-driven platforms to facilitate the rapid discovery of drug candidates and has a global network for validating computational results [5] Product Development - DA-1241 is a novel GPR119 agonist that promotes the release of gut peptides GLP-1, GIP, and PYY, which are involved in glucose and lipid metabolism, as well as weight loss [4] - In a 16-week Phase 2a study involving 109 subjects, DA-1241 demonstrated a favorable safety and tolerability profile, along with hepatoprotective and glucose-regulating effects in patients with presumed MASH [2][4] Collaboration Details - The collaboration with Syntekabio will leverage its DeepMatcher® AI platform to conduct large-scale virtual screening against over 1,700 validated protein targets, aiming to uncover new indications for DA-1241 while minimizing off-target effects [3] - Initial insights from this collaboration are expected later in the year, which could further validate DA-1241's therapeutic potential [3]

Summary of Conference Call for Citizens Inc. (CIA) Company Overview - Citizens Inc. is a diversified financial services company providing life, living benefits, and final expense insurance, along with other financial products to individuals and small businesses in the US, Latin America, and Asia [1][4] - The company is based in Austin, Texas, with a significant presence in Puerto Rico and operations in South America and Taiwan [5] Key Financial Metrics - The company has approximately $1.7 billion in assets [6] - In 2024, two-thirds of sales came from the US, while one-third came from international markets [6][7] - Citizens Inc. was noted as the fastest-growing mature life insurance company in the US in 2024 [7] Growth Strategies - The company is focusing on domestic growth strategies in the US, South Central America, and emerging Asian markets [4] - There has been a dramatic increase in the number of independent agents, growing from a few hundred to over 8,000 agents [6][10] - The company has entered the domestic final expense market, which has been a significant driver of growth [11] Operational Challenges - Despite a 49% growth in first-year premiums, the first-quarter net income was lower compared to the previous year due to initial market entry costs [12] - The company is focused on building operational capacity ("building the factory") to support future growth, which involves upfront expenses that will lead to revenue growth in subsequent years [13] International Expansion - Currently, about 10% of in-force revenue comes from Asia, primarily Taiwan, with plans to expand into other Asian markets such as Hong Kong, Thailand, and Indonesia by 2026 [16][17] - The company aims to solidify its growth plans in South America and the Caribbean, targeting countries with low current exposure [17] Product Development - Citizens Inc. is looking to expand its product offerings beyond life insurance to include investment products and living benefits [11][20] - The company plans to diversify its product categories, which currently include life insurance, investment-focused products, and living benefits [22][23] Client Retention and Revenue Streams - The current business model is primarily transactional, with clients typically purchasing one product [20] - Future strategies include expanding product offerings to existing clients to increase revenue per client [20] Conclusion - Citizens Inc. is positioned for growth with a strong focus on expanding its agent network, entering new markets, and diversifying its product offerings, despite facing initial operational challenges and the need for upfront investments [12][15][20]

Core Viewpoint - MetaVia Inc. has announced a private placement expected to generate approximately $10.0 million in gross proceeds, aimed at supporting the clinical development of its obesity treatment, DA-1726 [1][2]. Group 1: Private Placement Details - The offering includes the purchase of 9,479,345 shares of common stock at $0.71 per share and 4,605,162 pre-funded warrants at $0.709 each, with an exercise price of $0.001 [2]. - The private placement is priced at-the-market under Nasdaq rules, with the closing expected around May 12, 2025, subject to customary conditions [2]. Group 2: Regulatory and Compliance Information - The securities are being offered to certain institutional accredited investors and are not registered under the Securities Act, thus cannot be sold in the U.S. without an effective registration statement or applicable exemption [3]. - MetaVia plans to file a registration statement with the SEC for the resale of the shares issued in the private placement and to obtain stockholder approval for the underlying shares of the pre-funded warrants [3]. Group 3: Company Overview - MetaVia Inc. is focused on transforming cardiometabolic diseases, currently developing DA-1726 for obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [5]. - DA-1726 is a novel oxyntomodulin analogue acting as a dual agonist for GLP1R and GCGR, potentially leading to superior weight loss compared to selective GLP1R agonists [5]. - DA-1241 is a GPR119 agonist that promotes the release of gut peptides and has shown positive effects on liver inflammation and glucose metabolism in pre-clinical studies [5].

Core Insights - MetaVia Inc. reported promising results from its Phase 1 clinical trial of DA-1726, indicating a dose-dependent response in body weight reduction, with significant differences in BMI and body weight compared to placebo [1][2][4] - DA-1726 demonstrated a maximum weight loss of -6.3% and a mean weight loss of -4.3% at the 32 mg dose, alongside notable reductions in fasting glucose and waist circumference [3][4] - The drug showed a favorable safety profile, with no significant cardiovascular effects observed, and a slight decrease in heart rate across most treatment groups [4][7] Company Overview - MetaVia Inc. is a clinical-stage biotechnology company focused on developing treatments for cardiometabolic diseases, particularly obesity [10] - The company is advancing DA-1726, a dual agonist targeting GLP-1 and glucagon receptors, which aims to improve weight loss outcomes compared to existing therapies [9][10] Clinical Trial Details - The Phase 1 trial was a randomized, double-blind, placebo-controlled study involving 36 subjects, assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of DA-1726 [6] - The trial's primary endpoint was to evaluate the safety and tolerability of DA-1726, while secondary endpoints included pharmacokinetic assessments and exploratory metabolic parameters [6] Future Directions - MetaVia plans to conduct a Phase 1 Part 3 study to evaluate DA-1726 in patients who discontinued other GLP-1 agonists, aiming to demonstrate improved tolerability and weight loss outcomes [5] - Additional cohorts will be added to determine the maximum tolerated dose of DA-1726, with expectations of enhanced efficacy at higher doses [5]